Bliss Gvs Pharma Limited (BLISSGVS) Price & Analysis

Compare

3 Followers

BLISSGVS Stock Chart & Stats

₹144.75

-₹6.85(-3.92%)

At close: Jan 09 4:00 PM EST

₹144.75

-₹6.85(-3.92%)

Day’s Range― - ―

52-Week Range₹105.05 - ₹244.05

Previous CloseN/A

Volume571.01K

Average Volume (3M)104.36K

Market Cap

₹21.50B

Enterprise Value₹20.06B

Total Cash (Recent Filing)₹2.01B

Total Debt (Recent Filing)₹524.91M

Price to Earnings (P/E)18.6

Beta1.44

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.28%

Share Statistics

EPS (TTM)2.20

Shares Outstanding105,788,970

10 Day Avg. Volume77,644

30 Day Avg. Volume104,358

Financial Highlights & Ratios

PEG Ratio1.37

Price to Book (P/B)1.20

Price to Sales (P/S)1.56

P/FCF Ratio42.37

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetLow leverage and a high equity ratio provide durable financial flexibility: they allow the company to fund regulatory compliance, pursue tender-based export opportunities, sustain operations through industry cycles, and support strategic investments or M&A without stressing liquidity.

Improving Profitability & MarginsRising gross, EBIT and EBITDA margins indicate improving operational efficiency and cost control. Sustained margin expansion improves cash generation potential and internal funding for R&D, capacity, or marketing, strengthening long-term competitive position in generics and specialty segments.

Diversified Revenue StreamsA mix of domestic finished-dosage sales, export contracts and third-party manufacturing reduces customer and market concentration risk. Contract manufacturing smooths capacity utilization and revenues, while export access expands addressable markets and supports durable growth if regulatory access is maintained.

Bears Say

Variable Free Cash FlowInconsistent free cash flow growth constrains the firm's ability to fund capex, repay debt, return cash to shareholders, or invest in growth. Even with healthy operating conversion, variability requires ongoing working-capital discipline and may limit strategic flexibility over the medium term.

Exposure To Generics Pricing PressureA heavy presence in generics subjects the company to low barriers to entry, tender-driven pricing and margin erosion. Without durable differentiation, scale advantages, or protected products, revenue and margin volatility from competitive pricing remain structural risks for profitability sustainability.

Low Dividend YieldA very low dividend yield signals limited cash returned to shareholders and may reflect management prioritizing reinvestment or cash conservation. For income-focused investors, this reduces appeal and highlights a need for stronger and more consistent free cash flow to support future payout credibility.

Bliss Gvs Pharma Limited News

Bliss GVS Pharma Adds New Step-Down Subsidiary in DR Congo to Deepen African Reach

Bliss Gvs Pharma Limited ( ($IN:BLISSGVS) ) just unveiled an update. Bliss GVS Pharma Limited has expanded its...

2M ago

Bliss GVS Pharma Announces Special Window for Share Transfer Requests

The latest announcement is out from Bliss Gvs Pharma Limited ( ($IN:BLISSGVS) ). Bliss GVS Pharma Limited has...

4M ago

BLISSGVS FAQ

What was Bliss Gvs Pharma Limited’s price range in the past 12 months?

Bliss Gvs Pharma Limited lowest stock price was ₹105.05 and its highest was ₹244.05 in the past 12 months.

What is Bliss Gvs Pharma Limited’s market cap?

Bliss Gvs Pharma Limited’s market cap is ₹21.50B.

When is Bliss Gvs Pharma Limited’s upcoming earnings report date?

Bliss Gvs Pharma Limited’s upcoming earnings report date is May 13, 2026 which is in 57 days.

How were Bliss Gvs Pharma Limited’s earnings last quarter?

Bliss Gvs Pharma Limited released its earnings results on Feb 10, 2026. The company reported ₹2.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.2.

Is Bliss Gvs Pharma Limited overvalued?

According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bliss Gvs Pharma Limited pay dividends?

Bliss Gvs Pharma Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.28%. See more information on Bliss Gvs Pharma Limited dividends here

What is Bliss Gvs Pharma Limited’s EPS estimate?

Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bliss Gvs Pharma Limited have?

Bliss Gvs Pharma Limited has 105,788,970 shares outstanding.

What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?

Bliss Gvs Pharma Limited reported an EPS of ₹2.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.791%.

Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?

Currently, no hedge funds are holding shares in IN:BLISSGVS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bliss Gvs Pharma Limited

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.